Scarica l'app Stockscreener
5.40
0.55%
-0.03
Dopo l'orario di chiusura:
5.40
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$5.43
Aprire:
$5.45
Volume 24 ore:
720.61K
Relative Volume:
0.49
Capitalizzazione di mercato:
$308.79M
Reddito:
$5.82M
Utile/perdita netta:
$71.18M
Rapporto P/E:
5.4152
EPS:
0.9972
Flusso di cassa netto:
$-84.30M
1 W Prestazione:
-3.05%
1M Prestazione:
-13.04%
6M Prestazione:
+22.17%
1 anno Prestazione:
+0.75%
Intervallo 1D:
$5.335
$5.475
Intervallo di 1 settimana:
$5.335
$5.90
Portata 52W:
$4.00
$7.65
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Nome
Abeona Therapeutics Inc
Settore
Industria
Telefono
646-813-4701
Indirizzo
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Compare ABEO vs VRTX, REGN, MRNA, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
5.40 | 308.79M | 5.82M | 71.18M | -84.30M | 0.9972 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-03-05 | Iniziato | Oppenheimer | Outperform |
| 2024-07-03 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-30 | Iniziato | Stifel | Buy |
| 2020-11-11 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-09-18 | Iniziato | B. Riley FBR | Buy |
| 2020-02-10 | Iniziato | SVB Leerink | Outperform |
| 2019-12-10 | Ripresa | Cantor Fitzgerald | Neutral |
| 2019-08-15 | Downgrade | Maxim Group | Buy → Hold |
| 2019-08-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2019-07-26 | Downgrade | Mizuho | Buy → Neutral |
| 2019-06-27 | Iniziato | Mizuho | Buy |
| 2018-10-12 | Iniziato | Mizuho | Buy |
| 2018-06-05 | Iniziato | Seaport Global Securities | Buy |
| 2017-11-08 | Iniziato | SunTrust | Buy |
| 2017-10-16 | Reiterato | H.C. Wainwright | Buy |
| 2017-10-11 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-10-10 | Iniziato | Citigroup | Buy |
| 2017-10-05 | Reiterato | Maxim Group | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-07-18 | Reiterato | Maxim Group | Buy |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2017-01-06 | Iniziato | Jefferies | Buy |
| 2016-09-29 | Reiterato | Maxim Group | Buy |
Mostra tutto
Abeona Therapeutics Inc Borsa (ABEO) Ultime notizie
(ABEO) Volatility Zones as Tactical Triggers - Stock Traders Daily
ABEO S-8 & SEC Filings - Yahoo! Finance Canada
Abeona Therapeutics stock reiterated at Buy by H.C. Wainwright - Investing.com Nigeria
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc.ABEO - prnewswire.com
Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright - TradingView
ABEO Stock Gains On Approval For A Drug Abeona Sold, Rating For The One It Sells - Stocktwits
Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum - Yahoo Finance
3 Growth Companies With Up To 18% Insider Ownership - simplywall.st
Roth MKM Maintains Abeona Therapeutics(ABEO.US) With Buy Rating, Maintains Target Price $17 - Moomoo
ABEO Should I Buy - Intellectia AI
Abeona Therapeutics Price Target Raised to $30.00/Share From $28.00 by Cantor Fitzgerald - Moomoo
Cantor raises Abeona stock price target on partner drug approval By Investing.com - Investing.com Australia
Cantor Fitzgerald Maintains Abeona Therapeutics(ABEO.US) With Buy Rating, Raises Target Price to $30 - Moomoo
Abeona Therapeutics (ABEO) Congratulates Ultragenyx on FDA Appro - gurufocus.com
Abeona Stands to Collect Royalties After Ultragenyx's FDA Approval — Here's the Rest of the Week - Benzinga
Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA) - The Manila Times
A gene therapy for Sanfilippo syndrome gets U.S. approval. Abeona helped develop it. - Stock Titan
ABEO Maintained by Cantor Fitzgerald -- Price Target Raised to $30 - gurufocus.com
Investigation launched into Abeona Therapeutics over possible securities fraud after Q2 revenue report. - Pluang
Abeona Therapeutics Price Target Announced at $17.00/Share by Roth Capital - Moomoo
Roth/MKM initiates Abeona Therapeutics stock with buy rating By Investing.com - Investing.com Australia
Roth/MKM initiates Abeona Therapeutics stock with buy rating - Investing.com
Form 8K Abeona Therapeutics Inc For: 15 September By Investing.com - Investing.com Australia
Abeona Therapeutics (NASDAQ: ABEO) Releases Updated Investor Presentation for September 15 H.C. Wainwright Conference - Kalkine Media
Abeona Therapeutics activates eighth treatment center for RDEB therapy By Investing.com - Investing.com Nigeria
Abeona Therapeutics (ABEO) Expands Zevaskyn Treatment Network Am - GuruFocus
Abeona Therapeutics activates eighth treatment center for RDEB therapy - Investing.com India
Abeona Therapeutics Activates University of Florida Health as Eighth Qualified Treatment Center for ZEVASKYN in RDEB - Quiver Quantitative
Abeona Therapeutics® Announces Activation of University of - GlobeNewswire
Abeona Therapeutics Updates Investor Presentation at Conference - The Globe and Mail
ABEO: Strong ZEVASKYN launch, expanding access, and pipeline advances drive growth momentum - TradingView
Abeona Therapeutics (NASDAQ: ABEO) posts new deck for H.C. Wainwright conference - Stock Titan
Abeona at Cantor healthcare conference: slow launch, big rare-disease bet - Investing.com Canada
ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law - Business Wire
Don't Ignore The Insider Selling In Abeona Therapeutics - simplywall.st
Responsive Playbooks and the ABEO Inflection - Stock Traders Daily
Abeona Therapeutics director Mark Alvino sells $87,966 in shares By Investing.com - Investing.com Australia
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences - GlobeNewswire
Abeona Therapeutics director Mark Alvino sells $87,966 in shares - Investing.com
Director Mark Alvino Sells 15,000 Shares of Abeona Therapeutics Inc (ABEO) - GuruFocus
Abeona Therapeutics (ABEO) director sells 15,000 shares, still holds 62,065 - Stock Titan
Director plans Abeona (NASDAQ: ABEO) stock sale from equity awards - Stock Titan
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Stock Titan
Abeona Therapeutics Inc (ABEO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Abeona Therapeutics faces securities fraud prob... - Pluang
H.C. Wainwright Maintains Abeona Therapeutics(ABEO.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Abeona Therapeutics Inc Azioni (ABEO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):